Townsquare Capital LLC Acquires 670 Shares of Repligen Co. (NASDAQ:RGEN)

Townsquare Capital LLC lifted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 5.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 14,106 shares of the biotechnology company’s stock after buying an additional 670 shares during the period. Townsquare Capital LLC’s holdings in Repligen were worth $2,099,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Andra AP fonden bought a new stake in shares of Repligen during the 2nd quarter worth about $25,000. Lazard Asset Management LLC grew its holdings in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 136 shares during the last quarter. UMB Bank n.a. raised its position in shares of Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares during the period. Blue Trust Inc. lifted its stake in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares during the last quarter. Finally, International Assets Investment Management LLC bought a new stake in shares of Repligen during the 2nd quarter worth $33,000. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling

In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The trade was a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on RGEN shares. Benchmark reissued a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Wells Fargo & Company started coverage on Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price for the company. Wolfe Research started coverage on Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $190.25.

Repligen Stock Up 0.4 %

Shares of NASDAQ RGEN opened at $150.54 on Friday. The business has a fifty day moving average of $140.98 and a two-hundred day moving average of $142.65. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13. The stock has a market cap of $8.43 billion, a PE ratio of -406.86, a PEG ratio of 4.52 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the firm posted $0.23 EPS. As a group, equities research analysts expect that Repligen Co. will post 1.52 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.